FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955496722> ?p ?o ?g. }

• W2955496722 abstract "7004 Background: Flumatinib (FM), a derivative of imatinib (IM), is a novel BCR-ABL1 tyrosine kinase inhibitor (TKI). The aim of this open-label phase III study was to validate the efficacy and safety of FM in comparison with IM as frontline treatment in Chinese patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase (CML-CP). Methods: Randomization was stratified by Sokal score with a 1:1 allocation to each arm. Primary endpoints were major molecular response (MMR = BCR-ABL IS≤0.1%) rates at 6 and 12 months. Molecular responses were assessed at a central laboratory blinded to treatment allocations during the study. Efficacy endpoints were analyzed for the intention-to-treat populations. This study is registered with ClinicalTrials.gov, number NCT02204644. Results: 400 eligible patients were randomized and patient characteristics at baseline were similar in each arm. The full analysis set (FAS) consisted of 393 patients who received FM 600 mg (n = 196) or IM 400 mg (n = 197) tablets once daily. Compared with IM, FM resulted significantly higher induction of MMR rate (%; 95%CI) at 6 month (33.7; 27.06-40.29 vs 18.3; 12.88-23.67; P = 0.0005) and 12 month (48.5; 41.47-55.47 vs 33.0; 26.43-39.56; P = 0.0021) and also at 3 month (8.2; 4.33- 12.00 vs 2.0; 0.06-4.00; P = 0.0058). Significantly more patients in the FM than in the IM arm achieved a complete molecular response (BCR-ABL IS≤0.0032%) at 12 months. Early molecular response (BCR-ABL IS ≤ 10%) at 3 months and early CCyR at 6 months were also significantly higher with FM than IM (82.1; 76.78-87.50 vs 53.3; 46.33-60.27; P < 0.0001 and 60.71; 53.88-67.55 vs 49.75, 42.76, 56.73; P = 0.0332). FM has a safety profile similar to IM. The rates of grade 3/4 TEAEs of FM were similar to IM, 56.57% (112 of 198) vs 41.38% (87 of 196). However, the frequencies of some nonhematological and hematological adverse events were significantly lower in the FM than in the IM arm, such as rash (4.59% vs 12.63%, P = 0.0064) and eyelid edema (0.51 vs 14.65, P < 0.0001); leukopenia (30.61 vs 62.63, P < 0.0001) and neutropenia (30.10 vs 59.60, P < 0.0001). No specific TEAE was identified in each arm. Conclusions: This phase III study met its primary endpoints. Our study results suggest that FM is comparable to IM in its safety and superior in its efficacy profile at 3, 6 and 12 month time points. These results support FM as a frontline treatment option for patients with newly diagnosed CML-CP. Clinical trial information: NCT02204644." @default.
• W2955496722 created "2019-07-12" @default.
• W2955496722 creator A5005994170 @default.
• W2955496722 creator A5010680257 @default.
• W2955496722 creator A5016890292 @default.
• W2955496722 creator A5032457247 @default.
• W2955496722 creator A5036233749 @default.
• W2955496722 creator A5044514611 @default.
• W2955496722 creator A5048883481 @default.
• W2955496722 creator A5049178213 @default.
• W2955496722 creator A5056433537 @default.
• W2955496722 creator A5063481044 @default.
• W2955496722 creator A5063496433 @default.
• W2955496722 creator A5070538645 @default.
• W2955496722 creator A5071443000 @default.
• W2955496722 creator A5072453373 @default.
• W2955496722 creator A5072458792 @default.
• W2955496722 creator A5074069807 @default.
• W2955496722 creator A5075285660 @default.
• W2955496722 creator A5075861470 @default.
• W2955496722 creator A5086214965 @default.
• W2955496722 creator A5087592842 @default.
• W2955496722 date "2019-05-20" @default.
• W2955496722 modified "2023-09-26" @default.
• W2955496722 title "Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study." @default.
• W2955496722 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.7004" @default.
• W2955496722 hasPublicationYear "2019" @default.
• W2955496722 type Work @default.
• W2955496722 sameAs 2955496722 @default.
• W2955496722 citedByCount "4" @default.
• W2955496722 countsByYear W29554967222019 @default.
• W2955496722 countsByYear W29554967222021 @default.
• W2955496722 crossrefType "journal-article" @default.
• W2955496722 hasAuthorship W2955496722A5005994170 @default.
• W2955496722 hasAuthorship W2955496722A5010680257 @default.
• W2955496722 hasAuthorship W2955496722A5016890292 @default.
• W2955496722 hasAuthorship W2955496722A5032457247 @default.
• W2955496722 hasAuthorship W2955496722A5036233749 @default.
• W2955496722 hasAuthorship W2955496722A5044514611 @default.
• W2955496722 hasAuthorship W2955496722A5048883481 @default.
• W2955496722 hasAuthorship W2955496722A5049178213 @default.
• W2955496722 hasAuthorship W2955496722A5056433537 @default.
• W2955496722 hasAuthorship W2955496722A5063481044 @default.
• W2955496722 hasAuthorship W2955496722A5063496433 @default.
• W2955496722 hasAuthorship W2955496722A5070538645 @default.
• W2955496722 hasAuthorship W2955496722A5071443000 @default.
• W2955496722 hasAuthorship W2955496722A5072453373 @default.
• W2955496722 hasAuthorship W2955496722A5072458792 @default.
• W2955496722 hasAuthorship W2955496722A5074069807 @default.
• W2955496722 hasAuthorship W2955496722A5075285660 @default.
• W2955496722 hasAuthorship W2955496722A5075861470 @default.
• W2955496722 hasAuthorship W2955496722A5086214965 @default.
• W2955496722 hasAuthorship W2955496722A5087592842 @default.
• W2955496722 hasConcept C121608353 @default.
• W2955496722 hasConcept C126322002 @default.
• W2955496722 hasConcept C143998085 @default.
• W2955496722 hasConcept C170493617 @default.
• W2955496722 hasConcept C2777583451 @default.
• W2955496722 hasConcept C2778729363 @default.
• W2955496722 hasConcept C2778820342 @default.
• W2955496722 hasConcept C2779536868 @default.
• W2955496722 hasConcept C31760486 @default.
• W2955496722 hasConcept C42362537 @default.
• W2955496722 hasConcept C502942594 @default.
• W2955496722 hasConcept C535046627 @default.
• W2955496722 hasConcept C71924100 @default.
• W2955496722 hasConcept C98274493 @default.
• W2955496722 hasConceptScore W2955496722C121608353 @default.
• W2955496722 hasConceptScore W2955496722C126322002 @default.
• W2955496722 hasConceptScore W2955496722C143998085 @default.
• W2955496722 hasConceptScore W2955496722C170493617 @default.
• W2955496722 hasConceptScore W2955496722C2777583451 @default.
• W2955496722 hasConceptScore W2955496722C2778729363 @default.
• W2955496722 hasConceptScore W2955496722C2778820342 @default.
• W2955496722 hasConceptScore W2955496722C2779536868 @default.
• W2955496722 hasConceptScore W2955496722C31760486 @default.
• W2955496722 hasConceptScore W2955496722C42362537 @default.
• W2955496722 hasConceptScore W2955496722C502942594 @default.
• W2955496722 hasConceptScore W2955496722C535046627 @default.
• W2955496722 hasConceptScore W2955496722C71924100 @default.
• W2955496722 hasConceptScore W2955496722C98274493 @default.
• W2955496722 hasLocation W29554967221 @default.
• W2955496722 hasOpenAccess W2955496722 @default.
• W2955496722 hasPrimaryLocation W29554967221 @default.
• W2955496722 hasRelatedWork W1997730029 @default.
• W2955496722 hasRelatedWork W2005106433 @default.
• W2955496722 hasRelatedWork W2057206328 @default.
• W2955496722 hasRelatedWork W2074762197 @default.
• W2955496722 hasRelatedWork W2127133818 @default.
• W2955496722 hasRelatedWork W2224441552 @default.
• W2955496722 hasRelatedWork W2244509933 @default.
• W2955496722 hasRelatedWork W2245550381 @default.
• W2955496722 hasRelatedWork W2378200925 @default.
• W2955496722 hasRelatedWork W2395836758 @default.
• W2955496722 hasRelatedWork W2536808902 @default.
• W2955496722 hasRelatedWork W2565396484 @default.
• W2955496722 hasRelatedWork W2753271566 @default.
• W2955496722 hasRelatedWork W2755591879 @default.
• W2955496722 hasRelatedWork W2790815575 @default.
• W2955496722 hasRelatedWork W2889531937 @default.

• next